Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Santhera steigert Umsatz im H1 markant und verringert Verlust (Moneycab) +++ SANTHERA Aktie -5,79%

TELO GENOMICS Aktie

 >TELO GENOMICS Aktienkurs 
0.021 EUR    +23.5%    (TradegateBSX)
Ask: 0.023 EUR / 87720 Stück
Bid: 0.021 EUR / 97088 Stück
Tagesumsatz: 18000 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>TELO GENOMICS Performance
1 Woche: -26,0%
1 Monat: -33,3%
3 Monate: -25,3%
6 Monate: -37,8%
1 Jahr: -58,0%
laufendes Jahr: -45,2%
>TELO GENOMICS Aktie
Name:  TELO GENOMICS CORP. O.N.
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA87975M2085 / A2PV0Q
Symbol/ Ticker:  3D0A (Frankfurt)
Kürzel:  FRA:3D0A, ETR:3D0A, 3D0A:GR
Index:  -
Webseite:  https://www.telodx.com/
Profil:  Telo Genomics Corp is a biotechnology company focused on transforming the landscape of precision genomics applications. At the forefront of genomics-based diagnostics, its primary function is to develop high-impact tools for detecting and analyzing t..
>Volltext..
Marktkapitalisierung:  2.19 Mio. EUR
Unternehmenswert:  2.4 Mio. EUR
Umsatz:  -
EBITDA:  -1.39 Mio. EUR
Nettogewinn:  -1.48 Mio. EUR
Gewinn je Aktie:  -0.01 EUR
Schulden:  0.83 Mio. EUR
Liquide Mittel:  0.62 Mio. EUR
Operativer Cashflow:  -0.82 Mio. EUR
Bargeldquote:  0.46
Umsatzwachstum:  -
Gewinnwachstum:  10.57%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  TELO GENOMICS
Letzte Datenerhebung:  30.09.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 100.43 Mio. St.
Frei handelbar: 95.93%
Leerverk. Aktien: -
Rückkaufquote: 4.78%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: No rating
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -178.19%
Eigenkaprendite: -3055.75%
>Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
29.09.26 - 09:42
 Telo Genomics Corp.: Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing (Newsfile)
 
In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of c......
15.09.26 - 12:42
 Telo Genomics Corp.: Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse (Newsfile)
 
Proprietary TeloView blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than bone-marrow next-generation flow cytometry in a University of Athens c......
04.08.26 - 12:42
 Telo Genomics Corp.: Telo Genomics Grants Stock Options (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and p......
16.07.26 - 13:06
 Telo Genomics Corp.: Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and pr......
09.07.26 - 13:06
 Telo Genomics Corp.: Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced tel......
27.06.26 - 03:12
 Telo Genomics Corp.: Telo Genomics Announces Termination of Investor Relations Agreement (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and pr......
14.04.26 - 13:06
 Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and p......
31.03.26 - 14:09
 Telo Genomics appoints John Farlinger as CEO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.03.26 - 13:12
 Telo Genomics Corp.: Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and p......
09.03.26 - 12:30
 Telo Genomics Corp.: Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and pr......
27.02.26 - 21:48
 Telo Genomics Corp.: Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement (Newsfile)
 
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic an......
18.02.26 - 13:12
 Telo Genomics Corp.: Telo Genomics Closes First Tranche of Convertible Debentures Financing (Newsfile)
 
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp.......
29.01.26 - 14:06
 Telo Genomics Corp.: Telo Genomics Announces Appointment of John Price as Chief Financial Officer (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic ......
19.01.26 - 14:06
 Telo Genomics Corp.: Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000 (Newsfile)
 
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESToronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO......
18.12.25 - 22:24
 Telo Genomics Corp.: Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advance......
11.12.25 - 22:06
 Telo Genomics Corp.: Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests fo......
13.11.25 - 14:42
 Telo Genomics Corp.: Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025 (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its pro......
09.10.25 - 14:42
 Telo Genomics Corp.: American Society of Hematology Accepts Telo Genomics′ Abstract for Presentation at its 2025 Meeting and Exposition (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for......
30.09.25 - 22:42
 Telo Genomics Corp.: Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests ......
19.09.25 - 14:42
 Telo Genomics Corp.: Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests ......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer die Eitelkeit bei sich leugnet, besitzt sie gewöhnlich in so brutaler Form, daß er instinktiv vor ihr das Auge schließt, um sich nicht verachten zu müssen. - Friedrich Wilhelm Nietzsche
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!